Table 3.
I | Inotropics | Previous or current need for inotropics |
N | NYHA III–IV/Natriuretic peptides | Persisting NYHA III–IV or increased (NT-pro)BNP |
E | End-organ failure | Deteriorating kidney and/or liver function |
E | Ejection fraction | Severely depressed left ventricular function (ejection fraction <20%) |
D | Defibrillator shocks | Repeated ICD shocks |
H | Hospitalisations | More than 1 admission for heart failure in the last 12 months |
E | Edema or escalating diuretics | Persisting congestion or increasing diuretic dose |
L | Low blood pressure | Consistent low systolic blood pressure (<90–100 mm Hg) |
P | Prognostic medication | Inability to titrate evidence based medication (ACE inhibitor/ARB/beta blocker/MRA or ARNI) |
NYHA New York Heart Association, (NT-pro)BNP (N-terminal-pro) B‑type natriuretic peptide, ICD implantable cardioverter defibrillator, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, MRA mineralocorticoid receptor antagonist, ARNI angiotensin receptor neprilysin inhibitor